Bloom Energy Enters Northern European Markets with New Sales Agreement
27.4.2023 16:15:00 EEST | Business Wire | Press release
Bloom Energy (NYSE:BE) has signed an agreement with Elugie to provide a total of 9.75 megawatts (MW) of power from the Bloom Energy Server® at five commercial, industrial and data center sites in Belgium. It is Bloom’s first entry to the northern Europe market. Elugie, which has its headquarters in Riga, Latvia, with offices in Mechelen, Belgium, is an energy service company in the Benelux market of Belgium, the Netherlands and Luxembourg.
Bloom’s solid-oxide fuel cell platforms, to be delivered in late 2023 and early 2024, will include Bloom’s new compatibility with Combined Heat and Power (CHP) systems. Elugie and Bloom are in discussions about deploying additional Bloom energy platforms to sites in the Netherlands and the Baltic nations, comprised of Latvia, Lithuania and Estonia. Elugie is also in discussions with Bloom about the opportunity to deploy the hydrogen-producing Bloom Electrolyzer™.
The agreement with Elugie is another major step in Bloom’s expansion into Europe, following marketing partnership agreements with Telam for Spain and Portugal announced earlier this year, and energy platform sales to Cefla and Ferrari in Italy announced in 2022. It will be the largest deployment of Bloom’s new CHP feature, which is an important energy efficiency and climate-friendly technology for industrial and commercial electricity users in Europe.
“This is a big win in support of our focus to build international business sales,” said Tim Schweikert, Senior Managing Director of International Business Development, Bloom Energy. “We look forward to Elugie’s work in Belgium and the many markets that it serves. This builds on our activities to grow sales across Europe and also in target markets in Asia.”
“Elugie is proud of developing opportunities with Bloom for a total capacity of 9.75MW in Belgium,” says Bjorn Van Haver, founder, Elugie. “This partnership will bring utility-scale clean solutions to critical customers in the country. Our objective is also to deploy Bloom’s servers in the Netherlands and the Baltics. Elugie is an experienced EPC (engineering, procurement and construction company) in delivering energy-as-a-service.”
For more information about Bloom Energy’s CHP technology visit:
https://www.bloomenergy.com/applications/energy-server-with-heat-capture/
Forward-Looking Statements
This press release contains certain forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom’s expectations, strategy, priorities, plans or intentions. These forward-looking statements include, but are not limited to: Bloom’s expectations regarding collaboration with Elugie and/or its customers; any expected features, such as CHP, or benefits from or the size of the collaboration with Elugie or installations in northern Europe; Bloom’s international expansion plans; and Bloom’s long-term commitment to particular regions, policies or imperatives. More information on potential risks and uncertainties that may impact Bloom’s business are set forth in Bloom’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 21, 2023 as well as subsequent reports filed with or furnished to the SEC from time to time. Bloom assumes no obligation to, and does not currently intend to, update any such forward-looking statements.
About Bloom Energy
Bloom Energy empowers businesses and communities to responsibly take charge of their energy. The company’s leading solid oxide platform for distributed generation of electricity and hydrogen is changing the future of energy. Fortune 100 companies around the world turn to Bloom Energy as a trusted partner to deliver lower carbon energy today and a net-zero future. For the latest news and announcements on Bloom Energy, visit https://newsroom.bloomenergy.com/.
For more information on Bloom Energy, visit https://www.bloomenergy.com/.
About Elugie
Since 2000, Elugie founder Bjorn Van Haver has been striving for a sustainable energy transition, for this and future generations. Elugie a pioneer in hydrogen power stations, where hydrogen is ingeniously converted into socially responsible electricity for buildings: more sustainable, smarter, more efficient, cheaper and autonomous from the grid. Elugie is renting power stations connected to the Elugie smart grid platform and green gas contracts. Elugie’s mission is to reduce costs, reduce carbon and maximize efficiency in compliance with the European Union taxonomy for sustainable activities. For more information, visit www.Elugie.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005338/en/
Contact information
Bloom Energy Media Contact:
Virginia Citrano
press@bloomenergy.com
Bloom Energy Investor Relations:
Ed Vallejo
267.370.9717
Edward.Vallejo@bloomenergy.com
Elugie Media Contact:
Bjorn Van Haver
info@elugie.be
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
